Cosentyx® (secukinumab) in rheumatology
Cosentyx is indicated alone or in combination with methotrexate, for the treatment of active PsA in adult patients when the response to previous DMARDs has been inadequate, for the treatment of active AS in adults who have responded inadequately to conventional therapy, and for the treatment of active nr-axSpA, with objective signs of inflammation, as indicated by elevated C-reactive protein and/or MRI evidence, in adults who have responded inadequately to NSAIDs
Evolving rheumatology services to support PsA patients in a new world:
Presented live at BSR 2021 on Wednesday 28th April
Hear from our speakers Dr Antoni Chan, Dr Kirsten Mackay, Julie Begum and Anusha Patel, who discussed:
- The significance of early diagnosis, recognition, and treatment of the multiple manifestations of PsA
- Current approaches to service delivery to support patients with PsA, taking into account the contribution of supplementary services, such as nurse-led clinics
- The impact of COVID-19 on rheumatology services and patients, and potential solutions for when we begin to emerge from the pandemic
Watch Dr Kirsten Mackay’s presentation showing the management of two patient case studies
Watch the Q&A with the wider panel discussing ways of managing a PsA service during COVID-19
Take the next step
We’re here to support you with dedicated representatives up and down the country. Let us connect you with your local representative to discuss how you can get the most out of Cosentyx.
Or find out more using the links below...
AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; BSR, British Society for Rheumatology; COVID-19, coronavirus disease 2019; DMARD, disease-modifying antirheumatic drug; IL, interleukin; MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, psoriasis.